Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target from $169 to $166.
Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $166
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.